Research programme: isocitrate dehydrogenase inhibitors - Daiichi Sankyo/National Cancer Center

Drug Profile

Research programme: isocitrate dehydrogenase inhibitors - Daiichi Sankyo/National Cancer Center

Alternative Names: IDH1 inhibitors - Daiichi Sankya/National Cancer Cantre

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class 1 ring heterocyclic compounds; Antibodies; Antineoplastics; Isoxazoles
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Apr 2016 Preclinical trials in Cancer in Japan (unspecified route)
  • 01 Oct 2015 Daiichi Sankyo and the National Cancer Center have patent protection for isocitrate dehydrogenase 1 inhibitors
  • 22 May 2012 Early research in Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top